NINTEDANIB IMPACT ON SYMPTOMS FOR PATIENTS WITH PROGRESSIVE PULMONARY FIBROSIS

Abstract

New guidelines for IPF and progressive pulmonary fibrosis (PPF) for adults were released in 2022. According to these recommendations and clinical trials, nintendanib efficacy was approved for interstitial lung diseases with PPF. Dyspnoea and cough can have a significant impact on the lives of patients with pulmonary fibrosis. The secondary endpoint of the INBUILD clinical trial was the effect of nintedanib on health-related quality of life in patients with PPF. This goal was achieved by evaluating the previously unused “Living with Pulmonary Fibrosis” questionnaire